Which findings on chest radiographs is characteristic of non-small cell lung cancer (NSCLC)?

1. Lung Cancer: Non-Small Cell: Statistics. Cancer.Net. Available at https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. January 2019; Accessed: August 27, 2019.

2. Spiro SG, Gould MK, Colice GL, American College of Chest Physicians. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007 Sep. 132 (3 Suppl):149S-160S. [Medline].

3. Ravaioli A, Papi M, Pasquini E, Marangolo M, Rudnas B, Fantini M, et al. Lipoplatin monotherapy: A phase II trial of second-line treatment of metastatic non-small-cell lung cancer. J Chemother. 2009 Feb. 21(1):86-90. [Medline].

4. Ohba T, Yamasaki T, Endo Y, Furuie M, Ohtani Y, Inase N, et al. A phase I study of TS-1 plus carboplatin in patients with advanced non-small-cell lung cancer. J Chemother. 2009 Feb. 21(1):80-5. [Medline].

5. Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer. 2009 Jan. 10(1):28-35. [Medline].

6. Herbst RS, Lynch TJ, Sandler AB. Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. Clin Lung Cancer. 2009 Jan. 10(1):20-7. [Medline].

7. [Guideline] Expert Panel on Thoracic Imaging:., de Groot PM, Chung JH, Ackman JB, Berry MF, Carter BW, et al. ACR Appropriateness Criteria^® Noninvasive Clinical Staging of Primary Lung Cancer. J Am Coll Radiol. 2019 May. 16 (5S):S184-S195. [Medline]. [Full Text].

8. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995 Jan. 109(1):120-9. [Medline].

9. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009 Mar 10. 27(8):1227-34. [Medline].

10. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Feb 1. 27(4):591-8. [Medline].

11. Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008 Dec 10. 26(35):5755-60. [Medline].

12. Guerra L, Meregalli S, Zorz A, Niespolo R, De Ponti E, Elisei F, et al. Comparative evaluation of CT-based and respiratory-gated PET/CT-based planning target volume (PTV) in the definition of radiation treatment planning in lung cancer: preliminary results. Eur J Nucl Med Mol Imaging. 2013 Nov 1. [Medline].

13. Dane B, Grechushkin V, Plank A, Moore W, Bilfinger T. PET/CT vs. non-contrast CT alone for surveillance 1-year post lobectomy for stage I non-small-cell lung cancer. Am J Nucl Med Mol Imaging. 2013 Sep 19. 3(5):408-16. [Medline]. [Full Text].

14. [Guideline] Mazzone PJ, Silvestri GA, Patel S, et al. Screening for Lung Cancer: CHEST Guideline and Expert Panel Report. Chest. 2018 Apr. 153 (4):954-985. [Medline].

15. [Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-small-cell Lung Cancer (NSCLC). Version 5.2019. Available at https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. June 7, 2019; Accessed: July 27,2019.

16. Mattes MD, Moshchinsky AB, Ahsanuddin S, Rizk NP, Foster A, Wu AJ, et al. Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 Jun 15. [Medline].

17. Mattes MD, Weber WA, Foster A, Moshchinsky AB, Ahsanuddin S, Zhang Z, et al. A Predictive Model for Lymph Node Involvement with Malignancy on PET/CT in Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Aug. 10 (8):1207-12. [Medline].

18. Nair VS, Gevaert O, Davidzon G, Napel S, Graves EE, Hoang CD, et al. Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. Cancer Res. 2012 Aug 1. 72(15):3725-34. [Medline]. [Full Text].

19. [Guideline] Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1. 28 (suppl_4):iv1-iv21. [Medline]. [Full Text].

20. Miller WT. Value of clinical history. AJR Am J Roentgenol. 1990 Sep. 155(3):653-4. [Medline].

21. Swensen SJ, Brown LR, Colby TV. Lung nodule enhancement at CT: prospective findings. Radiology. 1996 Nov. 201(2):447-55. [Medline].

22. Hellwig D, Baum RP, Kirsch C. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: A systematic review. Nuklearmedizin. 2009 Jan 14. 48(1):[Medline].

23. Fried DV, Mawlawi O, Zhang L, Fave X, Zhou S, Ibbott G, et al. Stage III Non-Small Cell Lung Cancer: Prognostic Value of FDG PET Quantitative Imaging Features Combined with Clinical Prognostic Factors. Radiology. 2015 Jul 15. 142920. [Medline].

24. Deppen SA, Blume JD, Kensinger CD, Morgan AM, Aldrich MC, Massion PP, et al. Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis. JAMA. 2014 Sep 24. 312 (12):1227-36. [Medline].

Sat Sharma, MD, FRCPC Professor and Head, Division of Pulmonary Medicine, Department of Internal Medicine, University of Manitoba Faculty of Medicine; Site Director, Respiratory Medicine, St Boniface General Hospital, Canada

Sat Sharma, MD, FRCPC is a member of the following medical societies: American Academy of Sleep Medicine, American College of Chest Physicians, American College of Physicians-American Society of Internal Medicine, American Thoracic Society, Canadian Medical Association, Royal College of Physicians and Surgeons of Canada, Royal Society of Medicine, Society of Critical Care Medicine, World Medical Association

Disclosure: Nothing to disclose.

Bruce Maycher, MD 

Bruce Maycher, MD is a member of the following medical societies: American Roentgen Ray Society, Canadian Medical Association, Radiological Society of North America, Society of Thoracic Radiology

Disclosure: Nothing to disclose.

Bernard D Coombs, MB, ChB, PhD Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand

Disclosure: Nothing to disclose.

W Richard Webb, MD Professor, Department of Radiology, University of California, San Francisco, School of Medicine

Disclosure: Nothing to disclose.

Eugene C Lin, MD Attending Radiologist, Teaching Coordinator for Cardiac Imaging, Radiology Residency Program, Virginia Mason Medical Center; Clinical Assistant Professor of Radiology, University of Washington School of Medicine

Eugene C Lin, MD is a member of the following medical societies: American College of Nuclear Medicine, American College of Radiology, Radiological Society of North America, Society of Nuclear Medicine and Molecular Imaging

Disclosure: Nothing to disclose.

Kitt Shaffer, MD, PhD 

Kitt Shaffer, MD, PhD is a member of the following medical societies: American Roentgen Ray Society

Disclosure: Nothing to disclose.